The success of CAR-T in hematologic malignancies lays the foundation for treating solid tumors, and oncology results will provide crucial knowledges for converting CAR-T to other diseases.

the approved dose for BMS's Deucravacitinib treatment of psoriasis is 6mg QD, whereas the estimated dose for TAK279 clinical treatment of psoriasis is over 30mg QD. Why does TAK279 have BIC potential?

As research has progressed, CAR-T’s efficacy has been found to extend beyond cancer with great potential in treating autoimmunity, infections, fibrosis, aging-related diseases and more.

STAT6 is essential for IL-4 and IL-13 signal transduction, but it is downstream of the JAK/STAT pathway and is not utilized by other cytokines and growth factors.

While paying attention to the third-generation non-covalent BTK inhibitors, we can also consider other approaches to solve drug resistance.

Among the JAK Family Members, JAK3, which Only Regulates a Narrow Spectrum of γc Cytokines, Emerges as a Potential Ideal Target.

The results suggest that genetic variants in AVPR1A RS3-RS1 haplotypes may affect verbal learning and memory performance in part by modulating the left hippocampal CA2/3 structure and its rsFC with the thalamus.

Tumor-associated macrophages (TAMs) can inhibit tumor immune efficacy. Colony stimulating factor 1 receptor (CSF-1R)/CSF-1 pathway involved in regulating the function of TAMs. CSF-1R is a tyrosine kinase transmembrane receptor, also a member of the growth factor CSF-1/platelet derived growth factor (PDGF) receptor family.

Proliferating Cell Nuclear Antigen (PCNA) is a protein present in all eukaryotic cells that plays a crucial role in DNA synthesis and repair.

Moderna's R&D pipeline covers multiple areas, with major research areas including COVID-19 vaccines, influenza vaccines, preventive vaccines, systemic secretion and cell surface treatments; exploratory areas include tumor vaccines, local regeneration therapies, cell therapies and more.

These findings suggest that Puma inhibitors may have therapeutic potential for the treatment of these disorders.

On August 1, 2023, AstraZeneca has reached an agreement to pay $510 million to BMS to resolve patent lawsuit over its PD-L1 mAb Imfinzi (Durvalumab) and CTLA-4 mAb Imjudo (Tremelimumab).